Resumen de acción DCAL
Dishman Carbogen Amcis Limited presta servicios de investigación y fabricación por contrato a la industria farmacéutica en India y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de Dishman Carbogen Amcis Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹192.15 |
| 52 Week High | ₹283.00 |
| 52 Week Low | ₹113.10 |
| Beta | 1.2 |
| 1 Month Change | -16.53% |
| 3 Month Change | -19.54% |
| 1 Year Change | 68.63% |
| 3 Year Change | -8.96% |
| 5 Year Change | -19.69% |
| Change since IPO | -45.42% |
Noticias y actualizaciones recientes
Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Feb 25
Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 29Recent updates
Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Feb 25Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 29Is Dishman Carbogen Amcis (NSE:DCAL) Using Too Much Debt?
Jun 22Is Dishman Carbogen Amcis (NSE:DCAL) A Risky Investment?
Feb 14Dishman Carbogen Amcis (NSE:DCAL) Use Of Debt Could Be Considered Risky
Jun 22Shareholders Will Be Pleased With The Quality of Dishman Carbogen Amcis' (NSE:DCAL) Earnings
May 18Dishman Carbogen Amcis (NSE:DCAL) Has A Pretty Healthy Balance Sheet
Mar 14We Think Dishman Carbogen Amcis (NSE:DCAL) Is Taking Some Risk With Its Debt
Aug 23Why Dishman Carbogen Amcis Limited (NSE:DCAL) Could Be Worth Watching
Apr 29Dishman Carbogen Amcis (NSE:DCAL) Has A Somewhat Strained Balance Sheet
Mar 16A Look At Dishman Carbogen Amcis' (NSE:DCAL) Share Price Returns
Feb 23How Much Are Dishman Carbogen Amcis Limited (NSE:DCAL) Insiders Spending On Buying Shares?
Feb 05Is Dishman Carbogen Amcis Limited (NSE:DCAL) Popular Amongst Institutions?
Jan 23
What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Jan 10Is Now An Opportune Moment To Examine Dishman Carbogen Amcis Limited (NSE:DCAL)?
Dec 23Dishman Carbogen Amcis (NSE:DCAL) Takes On Some Risk With Its Use Of Debt
Dec 05Dishman Carbogen Amcis Limited (NSE:DCAL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Nov 17If You Had Bought Dishman Carbogen Amcis' (NSE:DCAL) Shares Three Years Ago You Would Be Down 47%
Oct 23What We Learned About Dishman Carbogen Amcis' (NSE:DCAL) CEO Compensation
Sep 27Is Now The Time To Look At Buying Dishman Carbogen Amcis Limited (NSE:DCAL)?
Sep 06Dishman Carbogen Amcis Limited's (NSE:DCAL) Share Price Could Signal Some Risk
Aug 03Dishman Carbogen Amcis Limited's (NSE:DCAL) Price In Tune With Earnings
Jul 20Market Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings
Jul 06Rentabilidad de los accionistas
| DCAL | IN Life Sciences | Mercado IN | |
|---|---|---|---|
| 7D | -0.7% | 2.4% | 3.0% |
| 1Y | 68.6% | 15.0% | 44.6% |
Rentabilidad vs. Industria: DCAL superó al sector Indian Life Sciences , que obtuvo un rendimiento del 19.6% el año pasado.
Rentabilidad vs. Mercado: DCAL superó al mercado Indian, que obtuvo un rendimiento del 46.4% el año pasado.
Volatilidad de los precios
| DCAL volatility | |
|---|---|
| DCAL Average Weekly Movement | 7.5% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.1% |
Precio estable de las acciones: El precio de las acciones de DCAL ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de DCAL (8%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1983 | 1,295 | Arpit Vyas | imdcal.com |
Dishman Carbogen Amcis Limited presta servicios de investigación y fabricación por contrato a la industria farmacéutica en India y a escala internacional. La empresa opera a través de los segmentos de Servicios de Investigación y Fabricación por Contrato y Moléculas Comercializables. También fabrica y suministra fármacos a granel, ingredientes farmacéuticos activos, catalizadores de transferencia de fase, compuestos de amonio cuaternario, fosforanos, reactivos wittig, productos de vitamina D, productos químicos finos, jabones para manos y cuerpo, desinfectantes, antisépticos, análogos de la vitamina D, colesterol, productos relacionados con la lanolina, formulaciones desinfectantes y diversos productos farmacéuticos y cosméticos, así como ingredientes farmacéuticos activos genéricos y de alta potencia.
Resumen de fundamentos de Dishman Carbogen Amcis Limited
| Estadísticas fundamentales de DCAL | |
|---|---|
| Capitalización bursátil | ₹30.13b |
| Beneficios(TTM) | -₹1.54b |
| Ingresos (TTM) | ₹25.80b |
1.2x
Ratio precio-ventas (PS)-19.5x
Ratio precio-beneficio (PE)¿Está DCAL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DCAL | |
|---|---|
| Ingresos | ₹25.80b |
| Coste de los ingresos | ₹7.32b |
| Beneficio bruto | ₹18.47b |
| Otros gastos | ₹20.02b |
| Beneficios | -₹1.54b |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 30, 2024
| Beneficios por acción (BPA) | -9.84 |
| Margen bruto | 71.62% |
| Margen de beneficio neto | -5.98% |
| Ratio deuda/patrimonio | 40.0% |
¿Cómo se ha desempeñado DCAL a largo plazo?
Ver rendimiento histórico y comparativa